May 19, 2022
By Dr. Marian Laderoute
As you are well aware, there has been much consternation over the safety of the COVID-19 vaccines with good reason [Seneff S et al, Food and Chemical Toxicity, April 2022]. Secondarily, at least two doses of the vaccines appear to increase the risk of SARS-CoV-2 infection, hardly a strategy to promote herd immunity, and the opposite of the rhetoric used by public health authorities to encourage vaccination.
Here is a summary from this review.
[…] agents which may prevent or reverse immunosenescence as the best strategy to reduce infection, hospitalization and/or COVID-19 severity. Agents which would abolish immunosenescence are alpha-fetoprotein (AFP) antagonists like zinc, flavonoids and especially ivermectin [Laderoute MP, Open Heart, April 29, 2021 see https://openheart.bmj.com/content/8/1/e001655.responses#ivermectin-may-prevent-and-reverse-immunosenescence-by-antagonizing-alpha-fetoprotein-and-downmodulating-pi3k-akt-mtor-hyperactivity]. Ivermectin has an amazing and scientifically validated effectiveness in the prophylaxis and treatment of COVID-19 [Kory P et al, Am J Therapeutics, April 2021]. A number of groups [McCullough PA et al, The American Journal of Medicine, January 2021; Kory P et al, J Clin Med Res, February 2022], have successfully employed protocols involving these AFP antagonists in the treatment of patients with COVID-19.
Since these recommended first-line protocols do not employ antivirals or monoclonal antibodies to spike protein, they do not select for resistance/variants. Rather they operate to improve host innate immune responses namely the trained immunity HERV-K102 protection system. Thus, these protocols can be used for any pandemic RNA virus, and is a key strategy for pandemic preparedness.
The importance of vitamin D in COVID-19 pathogenesis is two-fold. First it blocks the excessive inflammation associated with cytokine storm (Tallum A et al, PLoS One, 2016). Second, it prevents lipid body negative M1 foamy macrophages (which produce the protective HERV-K102 particles) from differentiating into lipid body positive M2 anti-inflammatory foamy macrophages (which do not produce HERV-K102 particles) [Oh J et al, Circulation , 2009]. Interestingly, the conversion of M1 to M2 foamy macrophages is favored in diabetics.
READ DETAILS HERE:
https://hervk102.substack.com/p/completed-and-submitted-a-literature?s=w